利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

129 条记录 (耗时 0.078 秒)

    Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
    53.
    发明授权
    Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis 有权
    用于诊断和预测类风湿性关节炎的瓜氨酸肽

    公开(公告)号：US08519096B2

    公开(公告)日：2013-08-27

    申请号：US13239329

    申请日：2011-09-21

    申请人： Nicholas Chi-Kwan Ling ,  Shui Long Wang ,  Dunrui Wang ,  Sharat Singh

    发明人： Nicholas Chi-Kwan Ling ,  Shui Long Wang ,  Dunrui Wang ,  Sharat Singh

    IPC分类号： G01N33/531 ,  G01N33/533 ,  C07K17/00

    CPC分类号： G01N33/564 ,  C07K14/4713

    摘要： The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided.

    摘要翻译： 本发明提供新颖的瓜氨酸肽，其用于帮助，协助，改善或促进风湿性疾病如类风湿性关节炎（RA）的诊断或预后的方法，以及用于鉴定与抗瓜氨酸化免疫反应的新型瓜氨酸肽 蛋白质抗体（ACPA）。 本发明还提供使用新的RF检测试剂检测类风湿因子（RF）的方法，以帮助，协助，改善或促进风湿性疾病如RA的诊断或预后。 还提供了包含本发明的新颖瓜氨酸肽和/或RF检测试剂中的至少一种的试剂盒。

    NOVEL GENOMIC BIOMARKERS FOR IRRITABLE BOWEL SYNDROME DIAGNOSIS
    55.
    发明申请
    NOVEL GENOMIC BIOMARKERS FOR IRRITABLE BOWEL SYNDROME DIAGNOSIS 审中-公开
    新型基因组生物标志物用于有用的BOWEL综合征诊断

    公开(公告)号：US20130005596A1

    公开(公告)日：2013-01-03

    申请号：US13479127

    申请日：2012-05-23

    申请人： Hua Gong ,  Sharat Singh ,  Nicholas Hoe

    发明人： Hua Gong ,  Sharat Singh ,  Nicholas Hoe

    IPC分类号： C40B30/04 ,  G01N27/62 ,  C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2800/065

    摘要： The invention provides novel biomarkers, kits, and methods of diagnosing, prognosing, and subtyping IBS. In one aspect, the invention provides novel genomic biomarkers for diagnosing, classifying, providing a prognosis for, and assigning therapy for IBS in a subject in need thereof. In another aspect, the present invention provides novel algorithms for the diagnosis and prognosis of IBS.

    摘要翻译： 本发明提供了诊断，预后和亚型IBS的新型生物标志物，试剂盒和方法。 一方面，本发明提供用于诊断，分类，提供有需要的受试者的IBS预后和分配治疗的新型基因组生物标志物。 另一方面，本发明提供了用于IBS诊断和预后的新颖算法。

    ASSAYS FOR THE DETECTION OF ANTI-TNF DRUGS AND AUTOANTIBODIES
    56.
    发明申请
    ASSAYS FOR THE DETECTION OF ANTI-TNF DRUGS AND AUTOANTIBODIES 有权
    用于检测抗TNF药物和自身抗体的方法

    公开(公告)号：US20120329172A1

    公开(公告)日：2012-12-27

    申请号：US13441727

    申请日：2012-04-06

    申请人： Sharat Singh ,  Shui Long Wang ,  Linda Ohrmund

    发明人： Sharat Singh ,  Shui Long Wang ,  Linda Ohrmund

    IPC分类号： G01N30/02 ,  G01N21/64

    CPC分类号： G01N33/564 ,  G01N33/5091 ,  G01N33/6854 ,  G01N2800/52

    摘要： The present invention provides assays for detecting and measuring the presence or level of anti-TNFα drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFα drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.

    摘要翻译： 本发明提供用于检测和测量样品中抗TNFα药物治疗剂和自身抗体的存在或水平的测定。 本发明可用于优化治疗和监测接受抗TNFα药物治疗剂的患者，以检测针对药物的自身抗体（例如HACA和/或HAHA）的存在或水平。

    Particles for diagnostic and therapeutic use
    57.
    发明授权
    Particles for diagnostic and therapeutic use 有权
    用于诊断和治疗用途的颗粒

    公开(公告)号：US07709273B2

    公开(公告)日：2010-05-04

    申请号：US11273275

    申请日：2005-11-14

    申请人： Sharat Singh ,  John S. Pease ,  Jacqueline Sadakian ,  Daniel B. Wagner ,  Edwin F. Ullman

    发明人： Sharat Singh ,  John S. Pease ,  Jacqueline Sadakian ,  Daniel B. Wagner ,  Edwin F. Ullman

    IPC分类号： G01N33/543 ,  G01N31/00

    CPC分类号： G01N33/587 ,  C12Q1/6816 ,  Y10T436/10 ,  C12Q2563/155 ,  C12Q2523/319

    摘要： Methods, compositions and kits are disclosed. The compositions are light emitting and comprise a polymeric matrix having dissolved therein a photoactive compound. The composition has the characteristic that, after activation of the photoactive compound, the rate of decrease in the intensity of light emission at any time during a 20-fold decrease in the intensity is proportional to the intensity of the light emission. In one embodiment the polymeric matrix is comprised of particles of about 20 nm to about 100 μm in diameter to which is bound a specific binding pair member. The particles generally comprise a polymeric matrix having dissolved therein about 1 to about 20% by weight of a dopant. The compositions may be used in methods for determining an analyte. A combination is provided comprising (1) a medium suspected of containing the analyte, (2) and the aforementioned composition. The photoactive substance is activated and the effect of the activating on the optical properties of the combination is detected. The presence and amount of the effect is related to the presence and amount of the analyte in the medium. Also disclosed are kits for use in an assay.

    摘要翻译： 公开了方法，组合物和试剂盒。 组合物是发光的并且包含其中溶解有光敏化合物的聚合物基质。 该组合物具有以下特征：在光活性化合物活化后，强度降低20倍的任何时间的发光强度的降低率与发光强度成比例。 在一个实施方案中，聚合物基质包含直径约20nm至约100μm的颗粒，其与特定结合对构件结合。 颗粒通常包含其中溶解约1至约20重量％的掺杂剂的聚合物基质。 该组合物可用于测定分析物的方法中。 提供的组合包括（1）怀疑含有分析物的介质，（2）和上述组合物。 光活性物质被激活，并且检测到激活对组合的光学性质的影响。 影响的存在和数量与介质中分析物的存在和数量有关。 还公开了用于测定的试剂盒。

    Kits employing generalized target-binding e-tag probes
    59.
    发明授权
    Kits employing generalized target-binding e-tag probes 失效
    套件采用广义目标绑定电子标签探针

    公开(公告)号：US07001725B2

    公开(公告)日：2006-02-21

    申请号：US09824851

    申请日：2001-04-02

    申请人： Sharat Singh ,  Tracy Matray ,  Ahmed Chenna

    发明人： Sharat Singh ,  Tracy Matray ,  Ahmed Chenna

    IPC分类号： C12Q1/68 ,  C07H21/02 ,  C07H21/04 ,  B65D85/42 ,  G01N27/26

    CPC分类号： C07H19/10 ,  C07H19/06 ,  C07H21/00 ,  Y10S435/808

    摘要： Kits for the multiplexed detection of the binding of, or interaction between, one or more ligands and target antiligands are provided. Detection involves the release of identifying tags as a consequence of target recognition. The kits include sets of electrophoretic tag probes or e-tag probes, a capture agent and optionally a cleaving agent. The e-tag probes comprise a detection region and a mobility-defining region called the mobility modifier, both linked to a target-binding moiety. In using the kits, target antiligands are contacted with a set of e-tag probes and the contacted antiligands are treated with a selected cleaving agent resulting in a mixture of e-tag reporters and uncleaved and/or partially cleaved e-tag probes. The mixture is exposed to a capture agent effective to bind to uncleaved or partially cleaved e-tag probes, followed by electrophoretic separation. In a multiplexed assay, different released e-tag reporters may be separated and detected providing for target identification.

    摘要翻译： 提供了用于多个检测一种或多种配体和靶抗配糖体的结合或相互作用的试剂盒。 检测涉及到识别标签作为目标识别的结果。 试剂盒包括电泳标签探针或电子标签探针，捕获剂和任选的裂解剂。 电子标签探针包括检测区域和称为迁移率调节剂的迁移率限定区域，两者都与靶结合部分连接。 在使用试剂盒时，将目标抗配糖与一组电子标签探针接触，并用选择的切割剂处理接触的抗配糖剂，导致电子标签报告子与未切割和/或部分切割的e-标签探针的混合物。 将混合物暴露于有效结合未切割或部分切割的e-标签探针的捕获剂，然后电泳分离。 在多重测定中，可以分离和检测不同的释放的电子标签记录器，以提供目标识别。